{"id":829294,"date":"2025-03-25T07:05:31","date_gmt":"2025-03-25T11:05:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/"},"modified":"2025-03-25T07:05:31","modified_gmt":"2025-03-25T11:05:31","slug":"ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/","title":{"rendered":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:8pt\">AC Immune to host symposium highlighting the company\u2019s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases<\/li>\n<li style=\"margin-bottom:8pt\">Multiple presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease (AD\/PD\u2122 2025) showcasing the diversity of the company\u2019s precision medicine pipeline<\/li>\n<\/ul>\n<p>\n        <strong>Lausanne, Switzerland, March 25, 2025 <\/strong>\u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) taking place in Vienna, Austria, on April 1 \u2013 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development of active immunotherapies featuring key opinion leaders, industry experts and AC Immune leadership.<\/p>\n<p>\n        <strong>Industry Symposium: Unlocking active immunotherapy for tailored prevention strategies in neurodegenerative diseases<\/strong><\/p>\n<p>Session Date\/Time: Wednesday, April 2, 2025, at 8:40 \u2013 10:40 am CET<br \/>Location: Hall A<\/p>\n<p>\n        <em>Opening and Closing Remarks: <\/em>Andrea Pfeifer, Ph.D., CEO of AC Immune<\/p>\n<p>\n        <em>Perspectives of disease-modification in Parkinson\u2019s disease<\/em><br \/>\n        <br \/>Presenter: Werner Poewe, M.D. (Medical University of Innsbruck)<br \/>Time: 8:50 \u2013 9:10 am CET<\/p>\n<p>\n        <em>Targeting alpha-synuclein in early Parkinson\u2019s disease: ACI-7104.056 in the Phase 2 trial VacSYn<\/em><br \/>\n        <br \/>Presenter: G\u00fcnther Staffler, Ph.D. (AC Immune)<br \/>Time: 9:10 \u2013 9:25 am CET<\/p>\n<p>\n        <em>Precision Prevention for Alzheimer\u2019s disease<\/em><br \/>\n        <br \/>Presenter: Philip Scheltens, M.D., Ph.D. (EQT Life Sciences, Amsterdam University Medical Center) Time: 9:25 \u2013 9:50 am CET<\/p>\n<p>\n        <em>The first active immunotherapy for AD prevention: ACI-35.030\/JNJ2056 in the Phase 2b Re<\/em>t<em>ain study<\/em><br \/>Presenter: Lennert Steukers, Ph.D. (Johnson &amp; Johnson Innovative Medicine)<br \/>Time: 9:50 \u2013 10:05 am CET<\/p>\n<p>\n        <em>Anti-Abeta active immunotherapy in early AD and DSAD: ACI-24.060 in the Phase 1b\/2 ABATE study<\/em><br \/>\n        <br \/>Presenter: Anke Post, M.D., Ph.D. (AC Immune)<br \/>Time: 10:05 \u2013 10:20 am CET<\/p>\n<p>The presentations will be followed by a Q&amp;A session, and a replay of the Industry Symposium will be available on the Events page of AC Immune\u2019s website after the event.<\/p>\n<p><strong>Oral Presentations<\/strong><\/p>\n<p><em>Morphomer\u00ae small molecules targeting Tau for the treatment of Alzheimer\u2019s disease<\/em><br \/>Presenter: Nicolas Preitner, Ph.D. (AC Immune) <br \/>Session: <strong>Translational Drug Development and Experimental Models<\/strong><br \/>Location: Hall C<br \/>Date\/Time: Saturday, April 5, 2025, at 16:40 \u2013 16:55 pm CET<\/p>\n<p>\n        <em>Development of Morphomer-antibody drug conjugates \u2013 a new class of drugs for neurodegenerative diseases<\/em><br \/>\n        <br \/>Virtual On-Demand Oral Presentation &#8211; <strong>Virtual OO &#8211; 186<\/strong><br \/>Presenter: Nampally Sreenivasachary, Ph.D. (AC Immune)<\/p>\n<p>\n        <em>Discovery and optimization of therapeutic small molecules targeting alpha-synuclein aggregation<\/em><br \/>\n        <br \/>Virtual On-Demand Oral Presentation &#8211; <strong>Virtual OO &#8211; 187<\/strong><br \/>Presenter: Elpida Tsika, Ph.D. (AC Immune)<\/p>\n<p><strong>Poster Presentations<\/strong><\/p>\n<p><em>Defining optimal thresholds for time-to-event endpoints for Parkinson\u2019s disease clinical trials<\/em><br \/>Poster on Board &#8211; <strong>SHIFT 02-066<\/strong><br \/>Presenter: Nicolas Sanchez (AC Immune)<\/p>\n<p><strong>Presentations and posters by our collaboration partners<\/strong><\/p>\n<p><em>Antibodies generated by JNJ-64042056, an active anti-pTau immunotherapy, in clinical trial ACI-35-1802 can block Tau seeding in neurons <\/em><br \/>Presenter: Clara Theunis, Ph.D. (Johnson &amp; Johnson Innovative Medicine)<br \/>Session: <strong>Abeta &amp; Tau Immunotherapies<\/strong><br \/>Location: Hall E<br \/>Date\/Time: Saturday, April 5, 2025, at 12:40 \u2013 12:55 am CET<\/p>\n<p>\n        <em>Immunization with JNJ-64042056 generates antibodies in non-human primates that inhibit Tau aggregation in a neuronal Tau seeding model<\/em><br \/>\n        <br \/>Poster on Board &#8211; <strong>SHIFT 02-636<\/strong><br \/>Presenter: Bruno Vasconcelos, Ph.D. (Johnson &amp; Johnson Innovative Medicine)<\/p>\n<p>\n        <strong>About AC Immune SA <\/strong>\n      <\/p>\n<p>AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen\u00ae and Morphomer\u00ae, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$4.5 billion in potential milestone payments plus royalties.<\/p>\n<p>SupraAntigen\u00ae is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer\u00ae is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.<\/p>\n<p>The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:490pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:306.4px;vertical-align: top\">\n            <strong>SVP, Investor Relations &amp; Corporate Communications<\/strong><\/p>\n<p>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email: gary.waanders@cimmune.com<\/p>\n<\/td>\n<td style=\"width:346.94px;vertical-align: top\">\n            <strong>U.S. Investors<\/strong><\/p>\n<p>Christina Tartaglia <br \/>Precision AQ <br \/>Phone: +1 332 322 7430<br \/>Email: <a href=\"mailto:christina.tartaglia@precisionaq.com\" rel=\"nofollow\" target=\"_blank\">christina.tartaglia@precisionaq.com<\/a><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:306.4px;vertical-align: top\">\n            <strong>International Media<\/strong><\/p>\n<p>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email: chris.maggos@cohesionbureau.com<\/td>\n<td style=\"width:346.94px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>Forward looking statements<\/strong>\n      <\/p>\n<p>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the\u00a0Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and\u00a0AC Immune\u00a0does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/4e2194e8-c03f-42fc-a4d3-8cdd1bfbceb8\">20250324_ACIU ADPD 2025 Curtain Raiser_final<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZjVmMjU1MzUtYmNkOC00NTg2LThhYzgtZjEzYTA1ZmY4ZmIwLTEwMzc0NDMtMjAyNS0wMy0yNS1lbg==\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 AC Immune to host symposium highlighting the company\u2019s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease (AD\/PD\u2122 2025) showcasing the diversity of the company\u2019s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) taking place in Vienna, Austria, on April 1 \u2013 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829294","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 AC Immune to host symposium highlighting the company\u2019s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease (AD\/PD\u2122 2025) showcasing the diversity of the company\u2019s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) taking place in Vienna, Austria, on April 1 \u2013 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development &hellip; Continue reading &quot;AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T11:05:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\\\/PD\u2122 2025\",\"datePublished\":\"2025-03-25T11:05:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/\"},\"wordCount\":980,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/\",\"name\":\"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\\\/PD\u2122 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\",\"datePublished\":\"2025-03-25T11:05:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\\\/PD\u2122 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 - Market Newsdesk","og_description":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 AC Immune to host symposium highlighting the company\u2019s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases Multiple presentations at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Disease (AD\/PD\u2122 2025) showcasing the diversity of the company\u2019s precision medicine pipeline Lausanne, Switzerland, March 25, 2025 \u2013 AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced upcoming presentations highlighting its precision medicine pipeline at the International Conference on Alzheimer\u2019s and Parkinson\u2019s Diseases (AD\/PD\u2122 2025) taking place in Vienna, Austria, on April 1 \u2013 5, 2025. AC Immune will host an industry symposium highlighting advances in the clinical development &hellip; Continue reading \"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T11:05:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025","datePublished":"2025-03-25T11:05:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/"},"wordCount":980,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/","name":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==","datePublished":"2025-03-25T11:05:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA3NTg3NCM0MDIxMDE2MDMjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-announces-upcoming-presentations-and-industry-symposium-on-active-immunotherapies-at-ad-pd-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD\/PD\u2122 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829294"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829294\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}